Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy - PubMed
6 hours ago
- #BCMA CAR-T therapy
- #Multiple myeloma
- #Hypogammaglobulinemia
- BCMA CAR-T therapy is effective for multiple myeloma but leads to hypogammaglobulinemia and infections.
- Severe hypogammaglobulinemia was most common post-therapy (42%), followed by moderate (26%) and mild (12%).
- 29.9% of patients developed severe infections, and 25% were hospitalized due to infections.
- Hypogammaglobulinemia increased from 69% pre-CAR-T to 80% post-CAR-T.
- Moderate to severe hypogammaglobulinemia persisted for over 12 months in 68% of patients.
- Pre-CAR-T hypogammaglobulinemia increased the risk of post-therapy hypogammaglobulinemia (OR: 16.07) and infections (IRR: 2.02).
- Lower IgG levels and larger pre-post IgG differences were linked to higher mortality risk (HR: 1.26 and 1.40, respectively).